PUNE, India, August 14, 2017 /PRNewswire/ --

According to a new market research report "Vaccine Market by Technology (Live, Conjugate, Toxoid, Recombinant), Disease (Influenza, DTaP, HPV, Hepatitis, Rotavirus, TT, Polio, MMR, Varicella, Dengue, TB, Rabies), Route (IM, SC, ID, Oral), End User (Pediatric, Adult) & Type - Forecast to 2022", published by MarketsandMarkets™, the market is expected to reach USD 49.27 Billion by 2022 from USD 34.30 Billion in 2017, at a CAGR of 7.5%.

     (Logo: http://photos.prnewswire.com/prnh/20160303/792302 )

Browse 92 Market Data Tables and 52 Figures spread through 204 Pages and in-depth TOC on "Vaccine Market"

http://www.marketsandmarkets.com/Market-Reports/vaccine-technologies-market-1155.html

Early buyers will receive 10% customization on this report. 

Conjugate vaccines to dominate the market in 2017 

Based on technology, the Vaccines Market is segmented into conjugate vaccines, inactivated and subunit vaccines, live attenuated vaccines, recombinant vaccines, and toxoid vaccines. In 2017, the conjugate segment is expected to account for the largest share of the Vaccines Market. The growth in this market is mainly driven by increasing investments by the government of developing countriesand rising prevalence of infectious diseases.

Download PDF Brochure: http://www.marketsandmarkets.com/pdfdownload.asp?id=1155

Based on disease indication, the pneumococcal segment is projected to grow at the highest CAGR during the forecast period. 

By disease indication, the Vaccines Market is segmented into pneumococcal disease, influenza, DTP, hepatitis, human papillomavirus (HPV), rotavirus, meningococcal disease, MMR (measles, mumps, and rubella), varicella, polio, dengue, and other disease indications. The pneumococcal segment is expected to register the highest rate during the forecast period. The growth in this segment can primarily be attributed to the increasing government investments in pneumococcal vaccination programs and high prevalence of pneumococcal disease.

Talk To Our Research Analysts: http://www.marketsandmarkets.com/speaktoanalyst.asp?id=1155

North America to dominate the Vaccines Market 

In 2017, North America is expected to dominate the market. The large share of this geographical segment is attributed to factors such as increasing investments by government organizations and companies to promote immunization as well as develop new vaccines. In 2017, Europe is expected to hold the second largest share of this market. Factors such as availability of funding and venture capital investments for the development of new vaccines and increasing government initiatives are expected to drive market growth in this region.

The Vaccines Market is highly competitive with the presence of several small and big players. Some of the players in the Vaccines Market are GlaxoSmithKline plc (U.K.), Pfizer, Inc. (U.S.), Merck & Co., Inc. (U.S.), Sanofi Pasteur SA (France), CSL Limited (Australia), Emergent BioSolutions, Inc. (U.S.), Johnson & Johnson (U.S.), MedImmune, LLC (U.S.), Astellas Pharma Inc. (Japan), Serum Institute of India (India), Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Japan), and Daiichi Sankyo Company, Limited (Japan).

Browse Related Reports: 

VETERINARY/ANIMAL VACCINES MARKET by PRODUCT (PORCINE, (COMPANION-CANINE), (LIVESTOCK-BOVINE), POULTRY, AQUACULTURE), DISEASES (RABIES, FMD, SWINE INFLUENZA, STRANGLES, FURUNCULOUS), TECHNOLOGY (DNA, RECOMBINANT, INACTIVATED, CONJUGATE) - FORECAST TO 2021

http://www.marketsandmarkets.com/Market-Reports/animal-veterinary-vaccines-market-1233.html

VACCINE ADJUVANTS MARKET BY PRODUCT TYPE (PARTICULATE, EMULSIONS, PATHOGEN, SAPONIN), ROUTE OF ADMINISTRATION (SUBCUTANEOUS, INTRAMUSCULAR), DISEASE TYPE (INFECTIOUS, CANCER), APPLICATION (RESEARCH, COMMERCIAL) & APPLICATION CATEGORY - FORECASTS TO 2021
http://www.marketsandmarkets.com/Market-Reports/vaccine-adjuvants-market-152603894.html

About MarketsandMarkets™: 

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their pain points around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators and strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.  

Contact:
Mr. Rohan
MarketsandMarkets™
701 Pike Street
Suite 2175, Seattle,
WA 98101, United States
Tel: +1-888-600-6441
Email: sales@marketsandmarkets.com

Visit MarketsandMarkets™ Blog@ http://mnmblog.org/market-research/healthcare/biotechnology

Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets

SOURCE MarketsandMarkets